

## **Supporting information**

### **Pre-clinical alterations in the serum of COL(IV)A3<sup>-/-</sup> mice as early biomarkers of Alport syndrome**

<sup>1,2</sup>Petra Muckova, <sup>1</sup>Sindy Wendler, <sup>3</sup>Diana Rubel, <sup>1</sup>Rita Büchler, <sup>1</sup>Mandy Alert, <sup>3</sup>Oliver Gross,

<sup>1</sup>Heidrun Rhode\*

<sup>1</sup>Institute of Biochemistry I, University Hospital Jena, Nonnenplan 2-4, 07740 Jena, Germany

<sup>2</sup>Clinic of Neurology, University Hospital Jena, Erlanger Allee 101, 07740 Jena, Germany

<sup>3</sup>Department of Nephrology and Rheumatology, University Medicine Göttingen,

Robert-Koch Str. 40, 37075 Göttingen, Germany

#### **Table S1**

Excel-folder on mass spectrometric data obtained by Sieve 2.0 and 2.1:

Protein ID, Description, Peptides, Frames, Hits, Ratios, Standard Deviation (StDev), pValue, Fraction number (1D\_2D) inclusive prefixes indicating sample pairs of A, 4.5 weeks; B, 6.0 weeks; and C, 7.5 weeks.

#### **Table S2**

Serum proteome alterations in AS-mice at week 4.5 - that are reversed by Ramipril.

#### **Table S3**

Serum proteome alterations in AS-mice at week 6.0 - that are reversed by Ramipril.

#### **Table S4**

Serum proteome alterations in AS-mice at week 7.5 - that are reversed by Ramipril.